41589-43-9

Usage

Uses

Used in Fragrance Industry:
Propanedioic acid, 2-cyclohexylidene-, 1,3-diethyl ester is used as a fragrance ingredient for its distinctive sweet, fruity, and floral odor. It is incorporated into perfumes and personal care products to provide a pleasant and appealing scent, enhancing the overall consumer experience.
Used in Perfume Formulation:
In the perfume industry, Propanedioic acid, 2-cyclohexylidene-, 1,3-diethyl ester is used as a key component in creating complex and harmonious fragrances. Its versatile scent profile allows it to blend well with other fragrance ingredients, contributing to the development of unique and captivating scents.
Used in Personal Care Products:
Propanedioic acid, 2-cyclohexylidene-, 1,3-diethyl ester is also utilized in personal care products such as soaps, shampoos, and lotions. Its sweet and floral aroma adds a pleasant scent to these products, making them more appealing to consumers and enhancing their overall sensory experience.
Potential Use in Pharmaceutical Industry:
While further research is needed, Propanedioic acid, 2-cyclohexylidene-, 1,3-diethyl ester may have potential applications in the pharmaceutical industry. Its unique properties could potentially be harnessed for various purposes, such as in the development of new drugs or as a component in drug delivery systems.
Potential Use in Chemical Industry:
Similarly, the chemical industry may also benefit from the properties of Propanedioic acid, 2-cyclohexylidene-, 1,3-diethyl ester. Its potential uses could include its incorporation into the development of new chemical products or as a component in existing ones, depending on its reactivity and compatibility with other chemicals.

InChI:InChI=1/C13H20O4/c1-3-16-12(14)11(13(15)17-4-2)10-8-6-5-7-9-10/h3-9H2,1-2H3

Upstream product

• 108-94-1 cyclohexanone 
• 105-53-3 diethyl malonate 
• 120-92-3 cyclopentanone 
• 2043-61-0 cyclohexanecarbaldehyde 

Downstream Products

• 143724-10-1 (7-Methoxy-2-methyl-2H-chromen-2-yl)-acetic acid ethyl ester 
• 78775-64-1 (1-Methylcyclohexyl)malonsaeure-diethylester 
• 128262-20-4 (1-cyanocyclohexyl)malonic acid diethyl ester 
• 2163-44-2 diethyl 2-cyclohexylmalonate 
• 200424-69-7 monoethyl α-(1-methylcyclohexyl)malonate 
• 361442-47-9 tert-butoxycarbonylamino-(1-methyl-cyclohexyl)-acetic acid 
• 361442-46-8 tert-butoxycarbonylamino-(1-methyl-cyclohexyl)-acetic acid ethyl ester 
• 361442-45-7 benzyloxycarbonylamino-(1-methyl-cyclohexyl)-acetic acid ethyl ester 
• 78775-71-0 (1-methyl-cyclohexyl)-malonic acid 
• 1262001-47-7 2-cyclohexylidene-1,3-propanediol 
• 1215295-54-7 ethyl 2-ethoxycarbonyl-3-(3-indolyl)-3-(cyclohexyl)propanoate 
• 143724-11-2 (6-Methoxy-2-methyl-2H-chromen-2-yl)-acetic acid ethyl ester 

Relevant academic research and scientific papers

Enantioselective Catalyst Systems from Copper(II) Triflate and BINOL–Silanediol

Silanediol and copper catalysis are merged, for the first time, to create an enhanced Lewis acid catalyst system for enantioselective heterocycle functionalization. The promise of this silanediol and copper catalyst combination is demonstrated in the enantioselective addition of indoles to alkylidene malonates to give rise to the desirable adducts in excellent yield and high enantiomeric excess. From these studies, 1,1′-bi-2-naphthol (BINOL)-based silanediols emerge as one-of-a-kind cocatalysts. Their potential role in the reaction pathway is also discussed.

Organic photocatalysis for the radical couplings of boronic acid derivatives in batch and flow

We report an acridium-based organic photocatalyst as an efficient replacement for iridium-based photocatalysts to oxidise boronic acid derivatives by a single electron process. Furthermore, we applied the developed catalytic system to the synthesis of four active pharmaceutical ingredients (APIs). A straightforward scale up approach using continuous flow photoreactors is also reported affording gram an hour throughput.

Protected amino hydroxy adamantane carboxylic acid and process for its preparation

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided. The provided compounds can be used for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

Azepanone-based inhibitors of human cathepsin S: Optimization of selectivity via the P2 substituent

A series of azepanone inhibitors of cathepsin S is described. Selectivity over both cathepsin K and cathepsin L was achieved by varying the P2 substituent. Ultimately, a balanced potency and selectivity profile was achieved in compound 39 possessing a 1-methylcyclohexyl alanine at P2 and nicotinamide as the P′ substituent. The cellular potency of selected analogs is also described.

Bronsted base-modulated Regioselective Pd-catalyzed intramolecular aerobic oxidative amination of alkenes: Formation of seven-membered amides and evidence for allylic C-H activation

A novel palladium-catalyzed intramolecular aerobic oxidative allylic C-H amination of olefins has been developed. Bronsted base can modulate the regioselectivity, favoring the formation of 7-membered rings. Mechanistic studies using deuterium-labeled substrates as probes support a rate-determining allylic C-H activation/irreversible reductive elimination pathway.

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α -Aminoacyl-L-cis-4,5-methanoprolinenitrile-Based Inhibitors

A series of methanoprolinenitrile-containing dipeptide mimetics were synthesized and assayed as inhibitors of the N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV). The catalytic action of DPP-IV is the principle means of degradation of glucagon-like peptide-1, a key mediator of glucose-stimulated insulin secretion, and DPP-IV inhibition shows clinical benefit as a novel mechanism for treatment of type 2 diabetes. However, many of the reversible inhibitors to date suffer from chemical instability stemming from an amine to nitrile intramolecular cyclization. Installation of a cyclopropyl moiety at either the 3,4- or 4,5-position of traditional 2-cyanopyrrolidide proline mimetics led to compounds with potent inhibitory activity against the enzyme. Additionally, cis-4,5-methanoprolinenitriles with β-branching in the N-terminal amino acid provided enhanced chemical stability and high inhibitory potency. This class of inhibitors also exhibited the ability to suppress prandial glucose elevations after an oral glucose challenge in male Zucker rats.

Optically active pyridonecarboxylic acid derivatives

N1 -(1,2-cis-2-halogenocyclopropyl)-substituted pyridonecarboxylic acid derivatives represented by the following formula (I) the terms of which are defined in the specification and the salts thereof are disclosed: STR1 These compounds have pate

Spiro compound

The present invention relates to spiro compounds of general formula I: STR1 wherein the substituents are herein below defined. The present invention relates to antibacterial spiro compounds which are of value as drugs for humans, veterinary drugs or drugs for use in fish culture or as preservatives, and to antibacterial compositions containing one or more of the same compounds as active ingredients.